Year: 2016
Type: article
Abstract: HUNTER STEVEN LOUDERBACKMu Therapeutics is a new company that is focusing on the development of a novel, opioid addiction vaccine.The vaccine creates an antagonistic action against relapse and prevents patients from feeling any physiological effects from the targeted opioids of abuse.The vaccine takes a multivalent approach in targeting both heroin and structurally related prescription opioids.The life-saving vaccine represents a critical tool for clinicians combating the growing heroin and prescription opioid epidemic sweeping the globe.The vaccine is currently in preclinical development, but Mu Therapeutics is planning to rapidly finish the necessary preclinical studies to translate the vaccine into human patient populations in clinical trials.Mu Therapeutics represents an enticing opportunity for investors and potential acquiring companies to help change the flawed paradigm of addiction treatment.The heroin and prescription opioid epidemic has left millions of families suffering from the loss of loved ones and the anguish from watching a loved one battle the grasp of opioid addiction.
Author: Hunter Louderback
Institution: Case Western Reserve University
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2617501323
